Dian Diagnosis (300244.SZ) announced first-half results, with net profit of 232 million yuan to mother, an increase of 2160.87% over the previous year

Zhitong Finance App News, Dean Diagnosis (300244.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 4.773 billion yuan, a year-on-year decrease of 3.30%. Achieved net profit attributable to shareholders of listed companies of 232 million yuan, an increase of 2160.87% over the previous year. Achieve net profit of 239 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss. Basic earnings per share were $0.3802.

During the reporting period, the diagnostic service business achieved revenue of 1,662 billion yuan, of which the ICL business achieved revenue of 1,579 billion yuan.

During the reporting period, the company's key disease business segments achieved contrarian growth. Among them, reproductive health business revenue increased 26% year on year, pathogen TNGs business revenue increased 27% year on year, and tumor associated diagnosis business revenue increased 34% year on year.